Value-of-information (VOI)
value-of-information techniques assess the expected costs of uncertainty surrounding a decision made on the basis of current information, in order to determine whether further research should be conducted and how this should be designed.
Venetoclax (Venclyxto®) in combination with obinutuzumab (Gazyvaro®). HTA ID: 20046
Venetoclax in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.
NCPE Assessment Process |
Complete |
Rapid review commissioned |
07/10/2020 |
Rapid review completed |
22/10/2020 |
Rapid Review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of venetoclax in combination with obinutuzumab compared with the current standard of care. |
Full pharmacoeconomic assessment commissioned by HSE |
27/10/2020 |
Pre-submission consultation with Applicant |
30/11/2020 |
Current Status |
Awaiting HTA submission from Applicant |